CN1406132A - 处理或抑制细胞损伤或细胞死亡的方法 - Google Patents

处理或抑制细胞损伤或细胞死亡的方法 Download PDF

Info

Publication number
CN1406132A
CN1406132A CN01804781A CN01804781A CN1406132A CN 1406132 A CN1406132 A CN 1406132A CN 01804781 A CN01804781 A CN 01804781A CN 01804781 A CN01804781 A CN 01804781A CN 1406132 A CN1406132 A CN 1406132A
Authority
CN
China
Prior art keywords
antagonists
tnf alpha
tnf
ischemic
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01804781A
Other languages
English (en)
Chinese (zh)
Inventor
G·S·弗里德里希斯
R·E·斯维洛
B·H·－N·乔
T·R·布里达尔
R·E·努曼
L·M·瓦纳
L·M·基拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1406132A publication Critical patent/CN1406132A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN01804781A 2000-02-10 2001-02-08 处理或抑制细胞损伤或细胞死亡的方法 Pending CN1406132A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50186200A 2000-02-10 2000-02-10
US09/501,862 2000-02-10

Publications (1)

Publication Number Publication Date
CN1406132A true CN1406132A (zh) 2003-03-26

Family

ID=23995312

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01804781A Pending CN1406132A (zh) 2000-02-10 2001-02-08 处理或抑制细胞损伤或细胞死亡的方法

Country Status (9)

Country Link
EP (1) EP1261364A1 (es)
JP (1) JP2003522155A (es)
CN (1) CN1406132A (es)
AR (1) AR033965A1 (es)
AU (1) AU2001236764A1 (es)
BR (1) BR0108193A (es)
CA (1) CA2399436A1 (es)
MX (1) MXPA02007683A (es)
WO (1) WO2001058473A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4583762B2 (ja) * 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
WO2013059410A1 (en) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with xylitol
EA029193B1 (ru) 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
EP2895188B1 (en) 2012-09-11 2017-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417563B1 (de) * 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
NL1007890C2 (nl) * 1997-12-24 1999-07-12 Dutch Trading Dutra B V Samenstel van een railsysteem, ten minste één stuk doek en een aantal bevestigingselementen voor bevestiging van het doek aan het railsysteem.
FR2779724B1 (fr) * 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1171148A2 (en) * 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders

Also Published As

Publication number Publication date
BR0108193A (pt) 2003-02-25
EP1261364A1 (en) 2002-12-04
AR033965A1 (es) 2004-01-21
JP2003522155A (ja) 2003-07-22
MXPA02007683A (es) 2002-12-13
WO2001058473A1 (en) 2001-08-16
CA2399436A1 (en) 2001-08-16
AU2001236764A1 (en) 2001-08-20

Similar Documents

Publication Publication Date Title
CN102245189B (zh) 改善梗死区灌注的组合物以及血管损伤修复方法
US20110218143A1 (en) Compositions and methods for tissue repair
US20060003932A1 (en) Method for promoting neovascularization
CN102316879B (zh) 药物制剂
EA009463B1 (ru) Применение эритропоэтина
CN110368360A (zh) 具有增加的注射速度的阿立哌唑制剂
CN102294016A (zh) 治疗血管相关疾病的包含肽的药物组合物
Albiero et al. Inhibition of SGLT2 rescues bone marrow cell traffic for vascular repair: role of glucose control and ketogenesis
CN1612747A (zh) 促红细胞生成素在预防或治疗心力衰竭中的用途
CN1406132A (zh) 处理或抑制细胞损伤或细胞死亡的方法
CN1867827A (zh) 用于诊断骨髓前体细胞(BMPs)和/或血液来源的循环前体细胞(BDPs)的心血管功能性的体外方法
Haque et al. High mobility group box 1 levels in on and off-pump cardiac surgery patients
JP2006239169A (ja) 胚性幹細胞から分化誘導した腸管様細胞塊における壁内神経系の形成方法
CN101528251A (zh) 用于预防和治疗糖尿病性周围神经病变的含有g-csf的治疗剂
KR20060018851A (ko) 조직 파괴를 수반하는 질환의 예방 및/또는 치료제
KR20180120766A (ko) 죽상동맥경화증의 치료용 약제의 제조에 있어서의 트리아세틸-3-하이드록시페닐아데노신의 용도
WO1998024467A1 (fr) Medicaments contre l'hepatite fulminante
CN114984219A (zh) Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途
JP6497827B1 (ja) エイコサノイド産生促進剤
US20040132635A1 (en) Method for prevention and treatment of kidney diseases
JP2022503847A (ja) 治療適用のための骨髄由来ニューロキニン－１受容体陽性（ｎｋ１ｒ＋）前駆細胞
AU749673B2 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
CN111848742B (zh) 一种多肽及其制药用途
JPH11286455A (ja) 骨髄異形成症候群治療薬
US20120142596A1 (en) Agent for stimulating mobilization of endothelial progenitor cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication